Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

We recently compiled a list of the 30 Best Stocks To Invest In According to Billionaires. In this article, we are going to ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...

Throughout last year’s entertainment awards season, Lilly took aim at the popular off-label use of GLP-1 drugs like its Mounjaro and Zepbound for cosmetic weight loss. A commercial released ...

The marketing push underscores Lilly’s efforts to further define itself as a reliable developer and distributor of its approved weight loss drugs — Mounjaro and Zepbound — by contrasting them to ...

Eli Lilly is investing an additional $27 billion to boost domestic drug production as President Donald Trump reaffirms his commitment to imposing tariffs to restore manufacturing in the U.S. The ...